Clinical Trials Logo

Clinical Trial Summary

Primary objective: To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in patient with chronic hepatitis B or D infection Secondary objectives: 1. To explore HBsAg loss and kinetics during the study period 2. To assess the anti-viral effect during the study period 3. To evaluate the rate of ALT normalization


Clinical Trial Description

There are 20 scheduled visits (screening, treatment weeks & follow-up weeks) for patients with > 0.5 log10 decline in HBsAg at TW12, which include screening visit, TW0 (baseline), TW2, TW4, TW6, TW8, TW10, TW12, TW13, TW15, TW17, TW19, TW21, TW23 (EOT), FW4, FW8, FW12, FW16, FW20 and FW24. There are 22 scheduled visits for patients with ≤ 0.5 log10 decline in HBsAg at TW12. These visits include screening visit, TW0 (baseline), TW2, TW4, TW6, TW8, TW10, TW12, TW13, TW16, TW17, TW19, TW21, TW23, TW25, TW27 (EOT), FW4, FW8, FW12, FW16, FW20 and FW24. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04638439
Study type Interventional
Source PharmaEssentia
Contact Wendy Hung, MS
Phone +886-2-2655-7688
Email Wanchu_Hung@pharmaessentia.com
Status Recruiting
Phase Phase 1
Start date December 2021
Completion date March 2023

See also
  Status Clinical Trial Phase
Completed NCT03329820 - Quality of Life and Health Utility of Patients With CHB Infections N/A
Recruiting NCT04030039 - Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
Recruiting NCT03210506 - The Changes of Cytokines During Antiviral Therapy N/A
Recruiting NCT03210493 - The Changes of Treg Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT03209037 - The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03210467 - The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT03209011 - The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03208998 - The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03587467 - Study on Gut Microbiota in Chronic HBV Infected Patients
Completed NCT05355467 - Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum Phase 4
Recruiting NCT04135235 - Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B